Nurix Therapeutics Ownership | Who Owns Nurix Therapeutics?
Nurix Therapeutics Ownership Summary
Nurix Therapeutics is owned by 120.84% institutional investors, 1.43% insiders. Fmr is the largest institutional shareholder, holding 14.61% of NRIX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.01% of its assets in Nurix Therapeutics shares.
NRIX Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Nurix Therapeutics | 120.84% | 1.43% | -22.27% |
Sector | Healthcare Stocks | 57.43% | 9.41% | 33.16% |
Industry | Biotech Stocks | 69.02% | 8.92% | 22.06% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Fmr | 10.63M | 14.61% | $200.35M |
Blackrock | 6.82M | 12.42% | $142.33M |
Blackrock funding, inc. /de | 7.68M | 10.55% | $144.61M |
Vanguard group | 4.35M | 5.97% | $81.86M |
Redmile group | 4.19M | 5.76% | $78.99M |
Baker bros. advisors lp | 3.88M | 5.33% | $73.14M |
State street | 2.71M | 4.93% | $56.53M |
Wellington management group llp | 3.59M | 4.93% | $67.57M |
Price t rowe associates inc /md/ | 3.01M | 4.13% | $56.66M |
Deep track capital, lp | 3.00M | 4.12% | $56.52M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Redmile group | 4.19M | 5.50% | $78.99M |
Commodore capital lp | 3.00M | 4.14% | $56.52M |
Soleus capital management | 2.10M | 2.49% | $39.62M |
Affinity asset advisors | 940.08K | 2.37% | $17.71M |
Deep track capital, lp | 3.00M | 2.11% | $56.52M |
Velan capital investment management lp | 97.89K | 1.59% | $1.84M |
Parkman healthcare partners | 532.17K | 1.34% | $10.03M |
Opaleye management | 378.50K | 1.25% | $7.13M |
Westhill financial advisors | 228.33K | 0.96% | $4.30M |
Vienna powszechne towarzystwo emerytalne s.a. vienna insurance group | 85.00K | 0.93% | $1.60M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Fmr | 10.63M | 0.01% | 10.05M |
Blackrock | 6.82M | 0.00% | 2.24M |
Commodore capital lp | 3.00M | 4.14% | 1.35M |
Ra capital management | 1.33M | 0.33% | 1.33M |
Driehaus capital management | 1.28M | 0.26% | 1.28M |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Bain capital life sciences investors | - | - | -1.13M |
Deep track capital, lp | 3.00M | 2.11% | -868.10K |
Ark investment management | 1.53M | 0.24% | -686.07K |
Morgan stanley | 1.99M | 0.00% | -541.10K |
Candriam s.c.a. | 634.63K | 0.07% | -427.33K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Driehaus capital management | 1.28M | 0.26% | 1.28M | $26.78M |
Point72 asset management | 872.96K | 0.04% | 872.96K | $16.45M |
Perceptive advisors | 330.61K | 0.17% | 330.61K | $6.23M |
Norges bank | 318.80K | 0.00% | 318.80K | $6.01M |
Darwin global management | 163.68K | 0.29% | 163.68K | $3.08M |
Sold Out
Holder | Change |
---|---|
Nelson, van denburg & campbell wealth management group | -9.00 |
True wealth design | -15.00 |
Capital performance advisors llp | -18.00 |
Lindbrook capital | -19.00 |
Larson financial group | -24.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 177 | 1.72% | 81,111,271 | 20.04% | 120 | 1.40% | 103 | 9.57% | 47 | -16.07% |
Sep 30, 2024 | 174 | -1.14% | 67,568,477 | 3.95% | 92 | 0.66% | 94 | -16.81% | 56 | 24.44% |
Jun 30, 2024 | 175 | 24.11% | 64,997,079 | 32.92% | 118 | 1.49% | 112 | 60.00% | 45 | 4.65% |
Mar 31, 2024 | 141 | 6.82% | 48,899,624 | 6.46% | 89 | 1.25% | 70 | 2.94% | 43 | 10.26% |
Dec 31, 2023 | 132 | 0.76% | 45,933,203 | 2.43% | 84 | 1.24% | 68 | 23.64% | 39 | -23.53% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Vanguard Total Stock Mkt Idx Inv | 2.29M | 3.01% | 454.00 |
iShares Russell 2000 ETF | 1.83M | 2.42% | -35.92K |
ARK Genomic Revolution ETF | 1.63M | 2.14% | - |
T. Rowe Price New Horizons | 1.45M | 2.05% | - |
US Small-Cap Growth II Equity Comp | 1.45M | 2.05% | -1.25K |
ARK Genomic Revolution | 1.51M | 1.99% | -691.71K |
Fidelity Select Health Care | 1.36M | 1.79% | 75.76K |
SPDR® S&P Biotech ETF | 1.24M | 1.64% | 9.40K |
Fidelity Select Biotechnology | 1.14M | 1.50% | - |
T. Rowe Price Integrated US SmCapGrEq | 985.71K | 1.39% | 492.85K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Mar 03, 2025 | van Houte Hans | Chief Financial Officer | Sell | $73.80K |
Mar 03, 2025 | van Houte Hans | Chief Financial Officer | Sell | $10.59K |
Jan 31, 2025 | Ring Christine | Chief Legal Officer | Sell | $2.05K |
Jan 31, 2025 | Ring Christine | Chief Legal Officer | Sell | $112.89K |
Jan 30, 2025 | Ring Christine | Chief Legal Officer | Sell | $5.91K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | - | 11 |
2024 Q4 | - | 10 |
2024 Q3 | - | 13 |
2024 Q2 | - | 9 |
2024 Q1 | - | 4 |
NRIX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools